KR20170054413A - 신규한 화합물 - Google Patents
신규한 화합물 Download PDFInfo
- Publication number
- KR20170054413A KR20170054413A KR1020177007735A KR20177007735A KR20170054413A KR 20170054413 A KR20170054413 A KR 20170054413A KR 1020177007735 A KR1020177007735 A KR 1020177007735A KR 20177007735 A KR20177007735 A KR 20177007735A KR 20170054413 A KR20170054413 A KR 20170054413A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- ethyl
- pharmaceutically acceptable
- acceptable salt
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *c1cc(N2CCOCC2)cc([C@@](CC(O)=O)CN2C[C@](CCc3ccc(CCCN4)c4n3)CC2)c1 Chemical compound *c1cc(N2CCOCC2)cc([C@@](CC(O)=O)CN2C[C@](CCc3ccc(CCCN4)c4n3)CC2)c1 0.000 description 3
- XHSGCUKRFWLWSE-LLVKDONJSA-N C(Cc1nc(nccc2)c2cc1)[C@H]1CNCC1 Chemical compound C(Cc1nc(nccc2)c2cc1)[C@H]1CNCC1 XHSGCUKRFWLWSE-LLVKDONJSA-N 0.000 description 1
- QESJLCKQPIPWOH-UHFFFAOYSA-N Cc1cc(C)n[n]1-c1cc(N2CCOCC2)cc(C(CC(O)=O)CN2CC(CCc3nc(NCCC4)c4cc3)CC2)c1 Chemical compound Cc1cc(C)n[n]1-c1cc(N2CCOCC2)cc(C(CC(O)=O)CN2CC(CCc3nc(NCCC4)c4cc3)CC2)c1 QESJLCKQPIPWOH-UHFFFAOYSA-N 0.000 description 1
- QESJLCKQPIPWOH-RXVAYIKUSA-N Cc1cc(C)n[n]1-c1cc(N2CCOCC2)cc(C(CC(O)=O)CN2C[C@H](CCc3nc(NCCC4)c4cc3)CC2)c1 Chemical compound Cc1cc(C)n[n]1-c1cc(N2CCOCC2)cc(C(CC(O)=O)CN2C[C@H](CCc3nc(NCCC4)c4cc3)CC2)c1 QESJLCKQPIPWOH-RXVAYIKUSA-N 0.000 description 1
- NIVBRIPUAQCFIE-QPPBQGQZSA-N OC(C[C@@H](CN1C[C@H](CCc2ccc(CCCN3)c3n2)CC1)c1cccc(N2CCOCC2)c1)=O Chemical compound OC(C[C@@H](CN1C[C@H](CCc2ccc(CCCN3)c3n2)CC1)c1cccc(N2CCOCC2)c1)=O NIVBRIPUAQCFIE-QPPBQGQZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1417018.7 | 2014-09-26 | ||
| GBGB1417018.7A GB201417018D0 (en) | 2014-09-26 | 2014-09-26 | Novel compounds |
| PCT/EP2015/071798 WO2016046241A1 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170054413A true KR20170054413A (ko) | 2017-05-17 |
Family
ID=51901174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177007735A Withdrawn KR20170054413A (ko) | 2014-09-26 | 2015-09-22 | 신규한 화합물 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10004724B2 (enExample) |
| EP (1) | EP3197895B1 (enExample) |
| JP (1) | JP6672276B2 (enExample) |
| KR (1) | KR20170054413A (enExample) |
| CN (1) | CN107074850A (enExample) |
| AU (1) | AU2015320874A1 (enExample) |
| BR (1) | BR112017006240A2 (enExample) |
| CA (1) | CA2962319A1 (enExample) |
| ES (1) | ES2796235T3 (enExample) |
| GB (1) | GB201417018D0 (enExample) |
| RU (1) | RU2017114352A (enExample) |
| WO (1) | WO2016046241A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| SMT202100089T1 (it) | 2016-11-08 | 2021-03-15 | Bristol Myers Squibb Co | Pirrol ammidi come inibitori delle integrine alfa v |
| EA201991121A1 (ru) | 2016-11-08 | 2019-11-29 | АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV | |
| CA3042710A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors |
| CN110214137A (zh) | 2016-11-08 | 2019-09-06 | 百时美施贵宝公司 | 作为αv整联蛋白拮抗剂的吲唑衍生物 |
| RS63483B1 (sr) | 2016-11-08 | 2022-09-30 | Bristol Myers Squibb Co | 3-supstituisane propionske kiseline kao inhibitori alfa v integrina |
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| AU2018229275B2 (en) | 2017-02-28 | 2021-12-23 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| ES2904645T3 (es) | 2017-11-07 | 2022-04-05 | Bristol Myers Squibb Co | Derivados de pirrolopirazina como inhibidores de integrina alfa v |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| WO2020081154A1 (en) | 2018-08-29 | 2020-04-23 | Morphic Therapeutic, Inc. | INHIBITORS OF ανβ6 INTEGRIN |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002508323A (ja) * | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| DE69829996T2 (de) | 1997-12-17 | 2006-02-23 | Merck & Co., Inc. (A New Jersey Corp.) | Integrin-rezeptor-antagonisten |
| CN1589145A (zh) | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| WO2000078317A1 (en) | 1999-06-23 | 2000-12-28 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1229910A4 (en) | 1999-10-04 | 2003-10-01 | Merck & Co Inc | integrin |
| YU32502A (sh) | 1999-11-08 | 2004-12-31 | Merck & Co.Inc. | Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina |
| US6933304B2 (en) | 2000-06-15 | 2005-08-23 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| JP2004504349A (ja) | 2000-07-26 | 2004-02-12 | メルク エンド カムパニー インコーポレーテッド | αｖインテグリン受容体拮抗薬 |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| AU2002246757B2 (en) | 2001-01-03 | 2006-02-02 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| US20050043344A1 (en) | 2002-12-20 | 2005-02-24 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists derivatives |
| DK2139882T3 (en) | 2007-03-23 | 2014-03-10 | Amgen Inc | 3-substituted quinoline or quinoxaline derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K) |
| US20100311736A1 (en) | 2007-10-22 | 2010-12-09 | Glaxosmithkline Llc | Pyridosulfonamide derivatives as p13 kinase inhibitors |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| EP3052515A4 (en) | 2013-09-30 | 2017-03-15 | The Regents of the University of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| RU2017132433A (ru) | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
| JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファｖベータ１インテグリン阻害剤及び使用方法 |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2014
- 2014-09-26 GB GBGB1417018.7A patent/GB201417018D0/en not_active Ceased
-
2015
- 2015-09-22 ES ES15767479T patent/ES2796235T3/es active Active
- 2015-09-22 JP JP2017516386A patent/JP6672276B2/ja not_active Expired - Fee Related
- 2015-09-22 RU RU2017114352A patent/RU2017114352A/ru unknown
- 2015-09-22 EP EP15767479.7A patent/EP3197895B1/en active Active
- 2015-09-22 AU AU2015320874A patent/AU2015320874A1/en not_active Abandoned
- 2015-09-22 CA CA2962319A patent/CA2962319A1/en active Pending
- 2015-09-22 CN CN201580052202.3A patent/CN107074850A/zh active Pending
- 2015-09-22 WO PCT/EP2015/071798 patent/WO2016046241A1/en not_active Ceased
- 2015-09-22 US US15/514,414 patent/US10004724B2/en not_active Expired - Fee Related
- 2015-09-22 BR BR112017006240A patent/BR112017006240A2/pt not_active Application Discontinuation
- 2015-09-22 KR KR1020177007735A patent/KR20170054413A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US10004724B2 (en) | 2018-06-26 |
| JP2017528506A (ja) | 2017-09-28 |
| GB201417018D0 (en) | 2014-11-12 |
| AU2015320874A1 (en) | 2017-03-09 |
| EP3197895A1 (en) | 2017-08-02 |
| RU2017114352A (ru) | 2018-10-26 |
| US20170290818A1 (en) | 2017-10-12 |
| ES2796235T3 (es) | 2020-11-26 |
| EP3197895B1 (en) | 2020-03-11 |
| JP6672276B2 (ja) | 2020-03-25 |
| BR112017006240A2 (pt) | 2017-12-12 |
| WO2016046241A1 (en) | 2016-03-31 |
| CA2962319A1 (en) | 2016-03-31 |
| CN107074850A (zh) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170054413A (ko) | 신규한 화합물 | |
| US10513517B2 (en) | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | |
| EP3433254B1 (en) | Naphthyridines as integrin antagonists | |
| US10450312B2 (en) | Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists | |
| KR101998000B1 (ko) | 신규한 화합물 | |
| WO2017158072A1 (en) | Citrate salt of the compound (s)-4-((s)-3-fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthydrin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl) butanoic acid | |
| HK1214262B (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170321 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |